Tower Research Capital (TRC)’s Astria Therapeutics ATXS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-1,353
| Closed | -$17.7K | – | 5124 |
|
|
2025
Q4 | $17.7K | Sell |
1,353
-917
| -40% | -$11K | ﹤0.01% | 3192 |
|
|
2025
Q3 | $16.5K | Sell |
2,270
-3,631
| -62% | -$24.6K | ﹤0.01% | 3472 |
|
|
2025
Q2 | $31.6K | Sell |
5,901
-1,701
| -22% | -$8.24K | ﹤0.01% | 3356 |
|
|
2025
Q1 | $40.6K | Buy |
7,602
+2,303
| +43% | +$16.1K | ﹤0.01% | 2372 |
|
|
2024
Q4 | $47.4K | Buy |
5,299
+2,766
| +109% | +$29.4K | ﹤0.01% | 2593 |
|
|
2024
Q3 | $27.9K | Sell |
2,533
-7,986
| -76% | -$88.8K | ﹤0.01% | 3048 |
|
|
2024
Q2 | $95.7K | Buy |
10,519
+4,013
| +62% | +$39.2K | ﹤0.01% | 2616 |
|
|
2024
Q1 | $91.6K | Buy |
6,506
+3,160
| +94% | +$39.4K | ﹤0.01% | 1872 |
|
|
2023
Q4 | $25.7K | Sell |
3,346
-11
| -0.3% | -$61 | ﹤0.01% | 3503 |
|
|
2023
Q3 | $25K | Buy |
3,357
+2,707
| +416% | +$23.1K | ﹤0.01% | 3170 |
|
|
2023
Q2 | $5.41K | Buy |
+650
| New | +$7.5K | ﹤0.01% | 4832 |
|
|
2023
Q1 | – | Sell |
-3,626
| Closed | -$54K | – | 5792 |
|
|
2022
Q4 | $54K | Buy |
3,626
+2,833
| +357% | +$29.2K | ﹤0.01% | 2285 |
|
|
2022
Q3 | $7K | Sell |
793
-1,280
| -62% | -$8.58K | ﹤0.01% | 4865 |
|
|
2022
Q2 | $6K | Buy |
2,073
+1,666
| +409% | +$7.47K | ﹤0.01% | 4891 |
|
|
2022
Q1 | $3K | Sell |
407
-1,551
| -79% | -$9.24K | ﹤0.01% | 5344 |
|
|
2021
Q4 | $11K | Buy |
+1,958
| New | +$12.9K | ﹤0.01% | 4382 |
|
|
2021
Q3 | – | Sell |
-1,640
| Closed | -$21K | – | 5752 |
|
|
2021
Q2 | $21K | Buy |
1,640
+800
| +95% | +$10.4K | ﹤0.01% | 3833 |
|
|
2021
Q1 | $15K | Sell |
840
-687
| -45% | -$12.4K | ﹤0.01% | 4092 |
|
|
2020
Q4 | $20K | Sell |
1,527
-1,400
| -48% | -$25K | ﹤0.01% | 3865 |
|
|
2020
Q3 | $109K | Buy |
2,927
+390
| +15% | +$15.5K | ﹤0.01% | 3091 |
|
|
2020
Q2 | $98K | Buy |
+2,537
| New | +$90.4K | ﹤0.01% | 2473 |
|
|
2020
Q1 | – | Sell |
-30
| Closed | -$1K | – | 3028 |
|
|
2019
Q4 | $1K | Buy |
+30
| New | +$946 | ﹤0.01% | 3202 |
|
|
2019
Q3 | – | Sell |
-118
| Closed | -$6K | – | 4072 |
|
|
2019
Q2 | $6K | Buy |
118
+101
| +594% | +$4.58K | ﹤0.01% | 2824 |
|
|
2019
Q1 | $1K | Hold |
17
| – | – | ﹤0.01% | 3526 |
|
|
2018
Q4 | $0 | Buy |
+17
| New | +$644 | ﹤0.01% | 3806 |
|
|
2017
Q4 | – | Hold |
0
| – | – | – | 3502 |
|
|
2017
Q3 | – | Sell |
-24
| Closed | -$2K | – | 3767 |
|
|
2017
Q2 | $2K | Buy |
24
+2
| +9% | +$166 | ﹤0.01% | 2312 |
|
|
2017
Q1 | $2K | Sell |
22
-2
| -8% | -$275 | ﹤0.01% | 2587 |
|
|
2016
Q4 | $5K | Buy |
24
+4
| +20% | +$979 | ﹤0.01% | 3021 |
|
|
2016
Q3 | $7K | Buy |
+20
| New | +$5.27K | ﹤0.01% | 2304 |
|
|
2016
Q1 | – | Sell |
-5
| Closed | -$2K | – | 4090 |
|
|
2015
Q4 | $2K | Sell |
5
-174
| -97% | -$83.5K | ﹤0.01% | 3684 |
|
|
2015
Q3 | $87K | Buy |
179
+168
| +1,527% | +$120K | 0.01% | 637 |
|
|
2015
Q2 | $8K | Buy |
+11
| New | +$8.31K | ﹤0.01% | 2869 |
|
Tower Research Capital (TRC)'s ATXS Position: Q1 2026 in Review
Tower Research Capital (TRC) sold out of Astria Therapeutics (ATXS) in Q1 2026, closing a stake of 1,353 shares — an estimated $17.7K sold.
Tower Research Capital (TRC) first reported a position in ATXS in Q2 2015 and held it in 32 quarters. The position peaked at $109K in Q3 2020. 0 funds tracked by Wall St. Rank hold ATXS as of Q1 2026.
- Tower Research Capital (TRC) reported no remaining Astria Therapeutics position as of Q1 2026 after selling out during the quarter.
- Tower Research Capital (TRC) sold 1,353 Astria Therapeutics shares in Q1 2026, an estimated $17.7K.
- Tower Research Capital (TRC) first reported a position in Astria Therapeutics in Q2 2015 and held it in 32 quarters.
- Tower Research Capital (TRC)'s Astria Therapeutics position peaked at $109K in Q3 2020.
- 0 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2026.
Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.